Jason Pitofsky - 06 Feb 2024 Form 3 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Vice President, Controller
Signature
/s/ Jason Pitofsky
Issuer symbol
REGN
Transactions as of
06 Feb 2024
Net transactions value
$0
Form type
3
Filing time
08 Feb 2024, 16:01:21 UTC
Next filing
07 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding REGN Common Stock 4,204 06 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding REGN Non-Qualified Stock Option (right to buy) 06 Feb 2024 Common Stock 487 $372.46 Direct F2
holding REGN Non-Qualified Stock Option (right to buy) 06 Feb 2024 Common Stock 1,905 $492.00 Direct F2
holding REGN Non-Qualified Stock Option (right to buy) 06 Feb 2024 Common Stock 1,978 $644.54 Direct F2
holding REGN Non-Qualified Stock Option (right to buy) 06 Feb 2024 Common Stock 3,978 $726.53 Direct F2
holding REGN Non-Qualified Stock Option (right to buy) 06 Feb 2024 Common Stock 3,264 $843.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of awards of restricted stock under the Second Amended and Restated 2014 Long-Term Incentive Plan or its predecessor.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.